Treatment of HLA-B27 Negative Bilateral Chronic Sacroiliitis

Initial Pharmacological Management

The American Family Physician recommends starting with the lowest effective dose of an NSAID as first-line therapy, with continuous evaluation and monitoring over 2-4 weeks 1
If the first NSAID is ineffective after 2-4 weeks, the American Family Physician suggests switching to a different NSAID before escalating therapy 1
The American College of Rheumatology strongly advises against the use of systemic glucocorticoids for axial disease, due to the potential for adverse effects 3, 4

The American Family Physician recommends that all patients be referred to a subspecialist for a structured exercise program, which is a strong recommendation, not optional 1, 3
Active supervised exercise interventions are superior to passive modalities, such as massage, ultrasound, and heat, according to the American College of Rheumatology 3, 4

The American College of Rheumatology recommends TNF inhibitors as the first biologic agent, with strong evidence supporting their use 5, 3, 4
Secukinumab or ixekizumab (IL-17 inhibitors) are strongly recommended alternatives if NSAIDs fail, according to the American College of Rheumatology 3, 4

If primary non-response to the first TNF inhibitor occurs, the American College of Rheumatology recommends switching to secukinumab or ixekizumab rather than trying a different TNF inhibitor 5, 3, 4
Tofacitinib is an option, but TNF inhibitors and IL-17 inhibitors are preferred, according to the American College of Rheumatology 5

The American College of Rheumatology advises against adding sulfasalazine or methotrexate to failed TNF inhibitor therapy; instead, switch to a different biologic 5, 3, 4
Sulfasalazine may be considered only for persistent peripheral arthritis, not for axial disease, according to the American College of Rheumatology 2

For isolated active sacroiliitis despite NSAIDs, locally administered parenteral glucocorticoids may be considered, according to the American College of Rheumatology 3, 4
This is a conditional recommendation with very low quality evidence, as stated by the American College of Rheumatology 3, 4

The American Family Physician advises against ruling out axial spondyloarthritis based solely on negative HLA-B27, as approximately 10% of cases are HLA-B27 negative 1
Inflammatory markers (ESR/CRP) have limited sensitivity (≤50%) and normal values do not exclude disease, according to the American College of Rheumatology 6

MRI may help evaluate disease activity when uncertain, but systematic serial radiographic monitoring is not recommended, according to the American College of Rheumatology 2
Once stable on biologic therapy, the American College of Rheumatology recommends not routinely discontinuing or tapering the biologic dose 5, 3, 4